人类基因治疗技术的迅速发展使越来越多针对先天性和获得性疾病的基因治疗方案进入临床试验,同时,逆转录病毒作为介导基因转染的载体也是目前基础和临床应用研究中最广泛使用的基因转移方法.迄今所掌握的研究资料表明,接受逆转录病毒介导基因治疗的患者中尚未发现因病毒感染导致的不良反应.因此,我们选择改造的缺陷型逆转录病毒载体 pLXSN,将分泌型抗肝癌单链双功能抗体基因(sFv-TNF-α) The rapid development of human gene therapy technology has brought more and more gene therapy programs for congenital and acquired diseases into clinical trials. At the same time, retrovirus as a carrier for gene transfection is also the most widely used in basic and clinical applications. The gene transfer method used. The research data available so far indicate that adverse reactions caused by viral infection have not been found in patients undergoing retrovirus-mediated gene therapy. Therefore, we chose to engineer the defective retroviral vector pLXSN. Secreted anti-hepatoma single-chain diabodies antibody gene (sFv-TNF-α)